IL33 and neoplasm: In addition, loss of IL33 expression may also promote tumor escape in patients with metastatic prostate carcinomas or kidney renal clear cell carcinomas, via down-modulation of genes involved in antigen processing and of major histocompatibility complex (MHC-I/HLA)-genes (113).